AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Subscribe To Our Newsletter & Stay Updated
